Pegasys + Copegus
peginterferon alfa-2a + Copegus (ribavirin)

PEGASYS Medication Guide
Pegasys Product Information
Copegus Medication Guide
Copegus Product Information

Articles on Pegasys + Copegus

Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients
11/17/09

Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12
10-16-2009

Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users
8-14-2009

Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study
7-28-2009

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6-23-2009

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009

IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response
5/22/09

Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients
5/08/09

Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
5/05/09

Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09

Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity
5/05/09

HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin
4/10/09

Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
4/07/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin
2/27/2009

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009

Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response
1/30/2009

Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
1/27/2009

SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study
12/12/2008

Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders
12/08/2008

Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review
12/082008

Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/02/2008

Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
12/02/2008

Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008

Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin
11/21/2008

Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin
11/18/2008

IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008

Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers
11/25/2008

IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia
11/07/2008

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
11/05/2008

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection
11/05/2008

Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin
11/05/2008

Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study
11/05/2008

Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C
10/21/2008

Pegylated Interferon plus Ribavirin Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals
10/17/08

24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response
10/14/08

Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin
10/14/08

Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C
10/10/08

Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma
10/10/08

Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial
9/09/2008

Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin
8/29/2008

Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin
8/19/2008

Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
8/12/2008

Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
8/05/2008

Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study
7/22/08

Comparison of the Pegylated Interferons Pegasys and PegIntron for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials
7/18/08

12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients
7/11/08

Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3
7/08/08

European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load
7/04/08

Pegylated Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial
6/03/08

Platelet Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in Prior Non-Responders (EPIC 3)
5/20/08

Rapid Virologic Response to Peginterferon alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained Virologic Response and Relapse
5/20/08

Amino Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated Interferon/ribavirin in Genotype 1b Patients
5/20/08

Pegylated Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection
5/09/08

Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin
5/06/08

How Ideal Is the IDEAL Trial?

PegIntron + Rebetol
peginterferon alfa-2b + Rebetol (ribavirin)

PEG-INTRON® Prescribing Information
REBETOL® Prescribing Information

Intron A + Rebetol
(interferon alfa-2b + ribavirin)

Articles on Intron A + Rebetol


HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
9-18-2009

FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues
9-04-2009

Genetic Variation Helps Explain Differences in Response to Interferon-based Therapy for Hepatitis C
8-21-2009

Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009

Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
7-07-2009

Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C
7-07-2009

Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009

Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
6-5-2009

HCV Viral Load Decline at Day 2 of Interferon-based Therapy Predicts Sustained Response, Explains Poorer Outcomes in African-Americans
6-2-2009

Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09

Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09

A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

Cyclical Treatment Interruption in Patients Taking Interferon-based Therapy for Chronic Hepatitis C
2/10/2009

CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C
12/05/2008

Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients
11/21/2008

Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C
11/14/2008

Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes
6/24/08

Selected Hepatitis C Patients with Decompensated Cirrhosis Can Benefit from Interferon-based Therapy prior to Liver Transplantation
6/10/08

Response to Controlled-release Interferon Alfa-2b (Locteron) in Genotype 1 Hepatitis C Patients
5/23/08

Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C
5/20/08

Clearance of HCV in Children at 5-Year Follow-up Is Predicted by Sustained Virologic Response at 24 Weeks Post Treatment With Interferon alfa-2b Plus Ribavirin
5/20/08

Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
5/20/08

Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin Non-Responders (NR)
5/20/08

Response to Interferon-based Therapy in Hispanic Patients with Chronic Hepatitis C
5/20/08

Rapid Virological Response Is a Stronger Predictor than HCV Genotype of Sustained Response to Interferon-based Therapy
5/13/08

Roferon A + Ribavirin
(interferon alfa-2a + ribavirin)

Articles on Intron A + Rebetol

HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
9-18-2009

FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues
9-04-2009

Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse
7-17-2009

Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
7-07-2009

Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C
7-07-2009

Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response
4/21/09

Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients
4/21/09

A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
4/13/09

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
4/03/09

CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C
12/05/2008

Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients
11/21/2008

Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C
11/14/2008

Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C
5/20/08

Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
5/20/08

Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin Non-Responders (NR)
5/20/08

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment
1/29/08

Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients
1/25/08